Prof. Jagattaran Das is an accomplished organic/medicinal chemist with over 25 years of experience in academia and corporate sectors. He received his Ph.D. in Chemistry from the Indian Institute of Science, Bangalore in 1994. After a series of postdoctoral studies at CNRS, Gif-sur-Yvette in France (Sponsor-Cancer Research Foundation, France), University of Konstanz in Germany (Alexander von Humboldt Fellow) and Tokyo University in Japan (Japan Science & Technology Fellow), he returned to India in 1999 and served as Director of Research at Dr. Reddy’s Laboratories (Drug Discovery) in Hyderabad (1999-2005), India followed by Vice President, Drug Discovery Research at Panacea Biotec, Mohali-India (2005-2018). During the Pharma industry stint, he held leadership roles in addition to technical roles. Over the years, he developed expertise in establishing research infrastructure, people management, and business strategy development. He also contributed substantially in curriculum and organization strategy development as a member of DAAC (Departmental Academic Advisory Committee), NIPER (National Institute of Pharmaceutical Education & Research)-Mohali and as a member of Board of Studies, Lovely Professional University, Punjab.

Thereafter, he joined Shoolini University, Solan followed by Baddi University of Emerging Sciences & Technologies, Baddi, India as Professor of Medicinal Chemistry. Prior to joining GITAM, he was a guest faculty at NIPER, Mohali.

He published expensively in peer-reviewed journals (27), co-authored in international patents (17) and discovered a new pharmacophore having anti-infective properties. He also developed an efficient procedure for bulk synthesis (8-10 kg scale) of DRL 13792, a triazole based NCE, which entered phase I clinical studies. He successfully mentored doctoral research scholar (Ph.D.) and M. Pharm students (Dissertations).

His research interests include design, synthesis, and SAR studies of molecules having medicinal applications. He has extensive experience in the synthesis of small molecules as NCE (New Chemical Entities) in the areas of antiinfectives, metabolic & CNS disorders. His research publications have a cumulative impact factor of 182; h-Index-20, i10-Index - 28, which has been cited around 2200 times.